Breakthrough ⁢in Neonatal Care: AI-Powered Software Approved for Managing Growth Retardation ⁢in Extremely Low Birth Weight Infants

The Ministry of Food and Drug Safety ​has ⁢announced the approval⁢ of a groundbreaking software, BT-580AI, developed by Bistos, designed to manage the risk of growth retardation in extremely low ‍birth weight infants.

This innovative software ⁤medical⁢ device utilizes artificial intelligence to analyze ⁢one week’s health information‍ data of extremely low ⁢birth weight (1.5 kg or less) infants admitted to the ⁣neonatal ‍ward. The AI-powered technology then indicates the risk of growth retardation at the time of‌ discharge (up to 28 days) ‍as either ‘high (high risk group)’ ⁣or ‘low (low risk group)’. This pioneering software is the first of its kind⁤ in Korea to receive approval ⁤for growth retardation​ management in extremely low ‌birth⁣ weight infants.

According⁣ to the Ministry of Food and Drug Safety,​ the predicted risk​ of growth retardation in⁤ extremely⁢ low birth weight infants, as ⁣determined ⁣by this software,⁢ will​ enable medical staff⁢ to provide targeted and intensive management. This includes enhanced ⁤nutritional supply, ultimately contributing⁣ to the healthy growth and development of⁢ these vulnerable⁣ infants.

The Ministry of Food and Drug⁤ Safety remains committed to supporting ⁢the development and supply of innovative software medical ⁣devices, leveraging artificial intelligence and ⁢regulatory ​science ‍expertise. This commitment aims to expand treatment opportunities for diseases that were previously challenging to diagnose⁤ and predict.